Trv Gp V LLC Invests $142.34 Million in Septerna, Inc. (NASDAQ:SEPN)

TRV GP V LLC purchased a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,215,591 shares of the company's stock, valued at approximately $142,337,000. Septerna makes up approximately 48.4% of TRV GP V LLC's investment portfolio, making the stock its largest position. TRV GP V LLC owned approximately 14.00% of Septerna as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in SEPN. New York State Common Retirement Fund acquired a new stake in shares of Septerna in the fourth quarter valued at about $32,000. Legal & General Group Plc acquired a new stake in shares of Septerna during the 4th quarter valued at approximately $42,000. Summit Investment Advisors Inc. acquired a new stake in shares of Septerna during the 4th quarter valued at approximately $45,000. PNC Financial Services Group Inc. purchased a new stake in shares of Septerna during the 4th quarter worth approximately $61,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Septerna in the 4th quarter worth approximately $185,000.

Insiders Place Their Bets

In other Septerna news, Director Alan Ezekowitz acquired 41,355 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were acquired at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the acquisition, the director now directly owns 104,101 shares of the company's stock, valued at $624,606. This trade represents a 65.91 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Gil M. Labrucherie bought 10,500 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was acquired at an average price of $5.51 per share, with a total value of $57,855.00. Following the completion of the purchase, the chief financial officer now directly owns 10,500 shares of the company's stock, valued at approximately $57,855. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 74,346 shares of company stock valued at $439,670.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SEPN shares. Wells Fargo & Company decreased their price objective on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Friday, March 28th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $50.00 price target on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Trading Down 0.5 %

Septerna stock traded down $0.04 during midday trading on Friday, reaching $6.43. 104,053 shares of the company were exchanged, compared to its average volume of 428,045. The company's 50-day moving average is $5.96. Septerna, Inc. has a 1 year low of $4.17 and a 1 year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. The firm had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.13 million. On average, equities analysts predict that Septerna, Inc. will post -7.11 EPS for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.